Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kjersem, Janne B ^a   Ikdahl, Tone ^a   Guren, Tormod ^a   Skovlund, Eva ^b   Sorbye, Halfdan ^c   Hamfjord, Julian ^a   Pfeiffer, Per ^d   Glimelius, Bengt ^e,f   Kersten, Christian ^g   Solvang, Hiroko ^a   Tveit, Kjell M ^a   Kure, Elin H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UPPSALA UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g Southern Hospital Trust   (Norway)

Author keywords

5 fluorouracil; Cetuximab; Colorectal cancer; LCS6; MiRNA polymorphism; Oxaliplatin

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LET 7 MICRORNA COMPLEMENTARY SITE GENE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL TIME;

3' UNTRANSLATED REGIONS; ADULT; AGED; ALLELES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING SITES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; LEUCOVORIN; MALE; MICRORNAS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PREVALENCE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; YOUNG ADULT;

EID: 84869195391     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-534     Document Type: Article

References (42)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.
2. Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765. 10.1056/NEJMoa0804385, 18946061.
4. Van CE, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019. 10.1200/JCO.2010.33.5091, 21502544.
5. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:4706-4713. 10.1200/JCO.2009.27.6055, 20921462.
6. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671. 10.1200/JCO.2008.20.8397, 19114683.
7. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705. 10.1200/JCO.2009.27.4860, 20921465.
8. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546. 10.1093/annonc/mdq632, 21228335.
9. De RW, Claes B, Bernasconi D, De SJ, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
10. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762. 10.1200/JCO.2011.38.0915, 22473155.
11. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114. 10.1016/S0140-6736(11)60613-2, 3159415, 21641636.
12. Grothey A, Lenz HJ. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol 2012, 30:1735-1737. 10.1200/JCO.2011.40.4194, 22473160.
13. Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Borger E, Teerenstra S, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012, 12:292. 10.1186/1471-2407-12-292, 3508829, 22804917.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
15. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269. 10.1038/nrc1840, 16557279.
16. Pichler M, Winter E, Stotz M, Eberhard K, Samonigg H, Lax S, et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer 2012, 106:1826-1832. 10.1038/bjc.2012.175, 22549179.
17. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 2010, 9:3396-3409. 10.1158/1535-7163.MCT-10-0137, 20881268.
18. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003, 1:882-891.
19. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28:1385-1392. 10.1038/onc.2008.474, 19137007.
20. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010, 17:F19-F36. 10.1677/ERC-09-0184, 19779035.
21. King CE, Wang L, Winograd R, Madison BB, Mongroo PS, Johnstone CN, et al. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene 2011, 30:4185-4193. 10.1038/onc.2011.131, 3165068, 21625210.
22. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006, 29:903-906. 10.1248/bpb.29.903, 16651716.
23. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647. 10.1016/j.cell.2005.01.014, 15766527.
24. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008, 68:8535-8540. 10.1158/0008-5472.CAN-08-2129, 2672193, 18922928.
25. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 2011, 12:377-386. 10.1016/S1470-2045(11)70044-4, 3488438, 21435948.
26. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010, 70:6509-6515. 10.1158/0008-5472.CAN-10-0689, 2923587, 20647319.
27. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, et al. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One 2012, 7:e37891. 10.1371/journal.pone.0037891, 3360659, 22662244.
28. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011, 17:3742-3750. 10.1158/1078-0432.CCR-10-3405, 3107901,3107901, 21385923.
29. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31:4559-4566.
30. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, et al. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009, 30:1003-1007. 10.1093/carcin/bgp099, 2691138, 19380522.
31. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, et al. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 2011, 17:7723-7731. 10.1158/1078-0432.CCR-11-0990, 21994416.
32. Ryan BM, Robles AI, Harris CC. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC-letter. Clin Cancer Res 2012, 18:3487-3488. 10.1158/1078-0432.CCR-12-0250, 22669132.
33. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 2010, 10:458-464. 10.1038/tpj.2010.9, 20177422.
34. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011, 22:104-109. 10.1093/annonc/mdq315, 20603437.
35. Winder T, Zhang W, El-Khoueiry A, Yang D, Pohl A, Lurje G, et al. Association of a germ-line variant in the K-ras 3' untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. ASCO Meeting Abstracts 2009, 27:4061.
36. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
37. Skjelbred CF, Saebo M, Hjartaker A, Grotmol T, Hansteen IL, Tveit KM, et al. Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer 2007, 7:228. 10.1186/1471-2407-7-228, 2228310, 18093316.
38. Rodriguez S, Gaunt TR, Day IN. Hardy-weinberg equilibrium testing of biological ascertainment for mendelian randomization studies. Am J Epidemiol 2009, 169:505-514. 2640163, 19126586.
39. Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, et al. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat 2011, 128:79-84. 10.1007/s10549-010-1080-z, 20676756.
40. Cerne JZ, Stegel V, Gersak K, Novakovic S. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer 2012, 12:105. 10.1186/1471-2407-12-105, 3342891, 22436609.
41. Ruzzo A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, et al. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ann Oncol 2011, 22:234-235.
42. Zhang W, Labonte MJ, Lenz HJ. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?. Ann Oncol 2011, 22:484-485. 10.1093/annonc/mdq704, 21278223.